Söndag 2 Februari | 09:01:57 Europe / Stockholm

Kalender

Tid*
2026-02-11 12:00 Bokslutskommuniké 2025
2025-11-12 08:30 Kvartalsrapport 2025-Q3
2025-08-27 08:30 Kvartalsrapport 2025-Q2
2025-05-28 N/A Årsstämma
2025-05-07 08:30 Kvartalsrapport 2025-Q1
2025-02-12 12:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-07-30 - Split QLIFE 2000:1
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-08 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2024-05-07 - Årsstämma
2024-02-08 - Bokslutskommuniké 2023
2024-01-16 - Extra Bolagsstämma 2023
2023-11-13 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-26 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2023-05-04 - Årsstämma
2023-03-24 - Extra Bolagsstämma 2022
2023-02-16 - Bokslutskommuniké 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-08 - Kvartalsrapport 2021-Q3
2021-08-16 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Extra Bolagsstämma 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-18 - Kvartalsrapport 2020-Q2
2020-05-22 - X-dag ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 - Årsstämma
2020-05-20 - Kvartalsrapport 2020-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.
2025-01-31 20:34:21

The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information.

The sanction relates to an incident in February 2023 when Thomas Warthoe forwarded an email with details related to a rights issue. The e-mail was forwarded to Peter Warthoe, CSO of the company and Thomas' brother. Peter Warthoe had previously been part of Qlife management but was no longer part of the management at the time of the forwarding. The rights issue was made public later in February 2023.

The information should not have been forwarded and Thomas Warthoe acknowledges his mistake.

"Peter and I have worked together for more than 20 years, and I forwarded this e-mail as a matter of routine. This was a clear mistake, and I should not have forwarded the e-mail. I have decided to accept the sanction, says Thomas Warthoe CEO of Qlife.

Lars Bangsgaard, the chairman of Qlife comments: "It is of course unfortunate that this happens, I am not particularly happy with this or the timing, but my confidence in Thomas Warthoe as CEO remains intact as I regard the issue as a mistake that can happen when you have worked closely together for so many years. We want to leave this behind us and concentrate on the future".